1/9 Something seemed familiar about the Q498R mutation. Then I remembered: @_b_meyer, examining in-vitro evolution of RBD mutations, predicted this mutation could emerge & lead to a variant with higher infectivity & immune evasion than any existing ones. nature.com/articles/s4156…
2/9 Q498R was not just one of many mutations they predicted: it was far & away their top candidate to become a major RBD mutation. It's the only novel mutation they mention in the abstract, noting that it requires the N501Y mutation to confer increased ACE2 binding affinity.
3/9 They used yeast to display human ACE2 receptors, then let various versions of SARS-CoV-2 S RBD compete against one another, with the highest binding-affinity RBDs advancing to the next round.
4/9 Random mutations were introduced in ways I'm not competent to explain, so I've included the relevant description in the screenshot below.
5/9 Mutations common in known VOCs quickly emerged, especially E484K and N501Y, which quickly became dominant. To me, this seems a good indication that their methods are valid & useful.
6/9 For library B5, they used ACE2 that required extremely high binding affinity, & this "resulted in the fixation of mutations E484K, Q498R and N501Y in all sequenced clones." Q498R was present in all the RBD variants with the highest binding affinity.
7/9 Figure 2f shows binding affinity on the x-axis and makes clear the ability of Q498R to increase ACE 2 binding affinity, hence their prediction that this mutation could emerge & spread.
8/9 Perhaps even more worrying, computer modeling by this team indicates that Q498R could confer a significant amount of immune evasion on any variant possessing it. No wonder this new SA variant is the first to worry @GuptaR_lab since the emergence of Delta.
9/9 I'm not an expert, so if I've made any errors or mischaracterized anything above, I welcome corrections from real experts. Besides @_b_meyer, the only other authors on the study on Twitter I could find were @Matthew_Gagne_ and @Nadav_Elad.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Very proud to be a co-author on this comprehensive preprint on the novel, growing saltation lineage BA.3.2, together with @Tuliodna, Darren Martin, Dikeledi Kekana, and lead author @graemedor. 1/9
I would normally write a summary 🧵 of the BA.3.2 mutational analysis here, but as much of my contribution parallels my previous BA.3.2 threads I'll just link to those here, w/brief descriptions of each.
BA.3.2 emerged in Nov 2024 after ~3 years of intrahost evolution with >50 new spike AA muts, but since then, it's changed very little. Could the drug molnupiravir (MOV) galvanize BA.3.2 into pursuing new evolutionary paths? A new 89-mut MOV BA.3.2 seq suggests it could. 1/11
Background on MOV: It's a mutagenic drug. Its purpose is to cause so many mutations that the virus becomes unviable & is cleared. But we've long known this often does not happen. Instead, the virus persists in highly mutated form & can be transmitted. 2/
I was an author on a paper published in @Nature that conclusively showed not only that MOV has created highly mutated, persistent viruses, but that these viruses have transmitted numerous times. See 🧵 below by lead author @theosanderson. 3/
The most valuable viral research tools—@nextstrain & CovSpectrum—are being destroyed, not only blocked from new data but now forbidden from even sharing info from the PAST. Why?
Because GISAID is run dictatorially by a con man, paranoid egomaniac, & liar named Peter Bogner. 1/
I use CovSpectrum & Nextstrain every day—& I'm not the only one. Every Covid thread I've ever posted here has relied partly on CovSpectrum & Nextstrain for information & visuals. These vital tools have now been stolen from us by a world-class grifter. 2/ thinkglobalhealth.org/article/to-fin…
For years scientists knew something was very, very wrong with GISAID, but the breakout story (from which much of this 🧵is based) came 2 years ago in @ScienceMagazine from @sciencecohen & Martin Enserik. 3/ science.org/content/articl…
3/77 sequences from the latest Netherlands upload are BA.3.2 as well as 4/86 seqs from Queensland, Australia, consistent w/the steady, slow growth we've seen in Germany, the UK, Ireland, & much of Australia. 1/4
One interesting (and possibly coincidental) aspect of the BA.3.2 tree: Two large branches have NSP14 mutations at adjacent AA residues—ORF1b:T1896I and ORF1b:H1897Y. 2/4
I don't have any idea what functional effects either of these mutations would have. They are both C->T mutations, which is the most common type, but they've been relatively uncommon throughout the pandemic, with fewer than 8000 sequences combined. 3/4
The first instance involved a small cluster of sequences that hospitalized several people & resulted in the death of a young child in early 2022. More on this one later. 2/15
The most recent example requires some background. In late 2024, a spectacularly mutated Delta appeared in Spain with 40 new spike mutations and numerous Cryptic markers.
Normally, I would write a thread about such a remarkable sequence, but there were some issues... 3/15
@StuartTurville has pointed out that WA delayed Covid spread longer than elsewhere in Australia. China has a somewhat similar immune history (as do other SE Asian countries). Perhaps BA.3.2 will do well in China once it arrives there? 2/4